Latest stocks in the news

Cytokinetics (CYTK), a late-stage biopharmaceutical firm specializing in cardiovascular disease treatments, has experienced a significant surge to multi-decade highs following the release of positive data from its SEQUOIA-HCM Phase 3 clinical trial for aficamten. Aficamten, an investigational once-daily pill, is designed to address hypertrophic cardiomyopathy (HCM), a severe heart condition characterized by the thickening of cardiac muscles, resulting in reduced pumping function and limitations in exercise capacity. With approximately 280,000 diagnosed HCM cases in the U.S. and an estimated 400,000-800,000 undiagnosed cases, CYTK is optimistic about aficamten becoming the preferred treatment for physicians and patients based on the promising Phase 3 trial outcomes. The drug exhibited significant enhancement in exercise capacity compared to the placebo, showing increased peak oxygen uptake measured through cardiopulmonary exercise testing (CPET) with a least square mean difference of 1.74 mL/kg/min. Aficamten also demonstrated substantial and clinically meaningful improvements across all ten pre-specified secondary endpoints, maintaining good tolerability. Adverse events occurred in 5.6% and 9.3% of patients on aficamten and placebo, respectively. Looking ahead, CYTK aims to seek FDA approval for aficamten, anticipating the submission in the second half of 2024. Considering the favorable clinical trial data and the existence of a similar drug by Bristol-Myers Squibb (BMY) in the market, the approval prospects seem promising. If approved, aficamten could be a transformative asset for CYTK, marking its first commercially available treatment and potentially evolving into a multi-billion-dollar product, making the company more appealing to potential suitors. Recent reports of takeover interest in Cytokinetics suggest increased attention amid generally slow deal-making, especially within the pharmaceutical and biotech sectors, which have seen heightened M&A activity. The overall implication is that CYTK is poised to transition from a late-stage biopharmaceutical entity to a commercial-stage company, elevating its attractiveness for potential acquirers.

Amazon (AMZN) is venturing into the advertising arena by introducing an ad tier for its Prime Video service, scheduled to launch on January 29. This move, previously hinted at by the company last fall, integrates Prime Video with its comprehensive Prime subscription, encompassing various services like "free" delivery, Amazon Music, and more. With a minimal cost of $2.99 per month for Prime members to maintain an ad-free experience, the potential impact on Prime's annual service is expected to be negligible. Amazon assures that the commercials will be limited, aiming for significantly fewer ads than traditional TV and other streaming providers. For members who use the video service sparingly, the introduction of ads may go unnoticed, and Amazon cites the necessity to generate revenue for sustained investments in compelling content. The adoption of an advertising tier aligns with the industry trend, where most streaming services offer a budget-friendly option with ads. Even Netflix (NFLX), after years of resistance, has recently embraced the ad-tier model. Amazon, already incorporating ads in its Thursday Night Football broadcasts, focuses on adding ads to regular on-demand programming. Overall, this strategic move by Amazon to monetize its video streaming service is deemed wise, given the modest $2.99 monthly fee, likely prompting most users to choose an ad-free experience. Despite concerns about potential future price increases for Prime, currently priced attractively at $139 per year or $14.99 per month, the company's foray into the ad tier is perceived as a positive development for online ad platforms like TTD and MGNI. The stock's muted reaction is attributed to the anticipated nature of this news, which Amazon had hinted at months ago, and the additional factor of an FDA letter addressing potentially harmful pharmaceutical ingredients, possibly influencing the stock's performance.

Bristol Myers Squibb (BMY) has delivered a belated but significant holiday gift to RayzeBio (RYZB) investors by announcing its acquisition of RayzeBio for $62.50 per share in cash, totaling $4.1 billion in equity value, or $3.6 billion net of cash. This acquisition, resulting in a remarkable 104% premium over RayzeBio's closing price of $30.57 on Friday, has received unanimous approval from both companies' boards of directors and is anticipated to conclude in the first half of 2024. RayzeBio operates as a clinical-stage radiopharmaceutical therapeutics ("RPT") company with a primary focus on actinium-based RPTs and an ongoing pipeline of developmental programs. The allure for Bristol Myers Squibb lies in the potential of RPT technology to combat various cancerous tumors, particularly in solid tumors where more effective treatments are needed. RPTs work by binding to tumor cells and delivering targeted radiation to induce cancer cell death. Actinium-based RPTs, with their high potency and short firing range of the alpha-emitter, present advantages in terms of potential stronger efficacy and more targeted delivery compared to existing RPTs. Although RayzeBio has not commercially launched any products yet, its lead program, RYZ101, is in phase 3 development for treating gastroenteropancreatic neuroendocrine tumors and early-stage development for small cell lung cancer, among other potential tumor types. Despite the absence of an immediate financial boost for Bristol Myers Squibb, the company perceives the deal as fortifying its oncology portfolio and enhancing growth prospects in the latter half of the decade. Bristol Myers emphasizes that RPTs are already transforming cancer care, and RayzeBio is at the forefront of pioneering this novel modality. The acquisition aims to expedite RayzeBio's preclinical and clinical programs, and, in addition to gaining access to RPT technology, Bristol Myers will acquire a state-of-the-art manufacturing facility currently under construction in Indianapolis, with GMP drug production scheduled to commence in the first half of 2024. The significant premium paid by Bristol Myers, entirely in cash, underscores the perceived transformative potential of RayzeBio's RPT platform. Despite the $4 billion price tag not being colossal in comparison to Bristol Myers' $105 billion market cap, the cash transaction signals the strategic importance assigned to RayzeBio's technology. Beyond the premium, RayzeBio stands to benefit from the larger pharma company's deeper pockets, accelerating its development pipeline and creating opportunities with potential new customers, contingent on future approvals. As a notable side note, Fusion Pharma (FUSN), a clinical-stage oncology company focusing on radiopharmaceuticals as precision medicines, is trading higher in sympathy with this development.

Synopsys (SNPS), a provider of electronic design automation software for chip testing and design, experienced a sell-off in the final hour of Friday's session after a Wall Street Journal report hinted at the company's potential interest in acquiring Ansys (ANSS), a developer of engineering simulation software. Subsequent details of the rumored transaction emerged after Friday's close, with Reuters reporting that Ansys was fielding takeover offers exceeding $400 per share, representing a roughly 17% premium to Friday's opening price. Although no formal deal has been established, the outcome remains uncertain, as Ansys continues to trade below the speculated acquisition price. Reuters anticipates a formal announcement in the coming weeks. The strategic rationale behind a Synopsys/Ansys acquisition lies in Ansys' extensive experience in developing engineering simulation software, with a well-established competitive advantage spanning various industries. Ansys' simulation software entails significant training costs, creating a defensive revenue stream. While Ansys faced a revenue downturn in the last quarter, primarily due to additional export restrictions imposed by the U.S. Department of Commerce on certain Chinese businesses, this is perceived as a short-term challenge. Ansys boasts impressive margins, maintaining gross margins exceeding 90% in Q3, showcasing effective expense management by its leadership. However, this efficiency limits the potential for Synopsys to achieve substantial cost savings through expense reductions, thereby capping potential synergies. The rapid decline in Synopsys' shares following reports of a possible Ansys takeover can be attributed to concerns about the speculated high acquisition cost. Purchasing Ansys at $400 per share would result in valuation metrics such as 15x estimated FY23 revenue and 46x adjusted earnings, surpassing levels observed in several other software tech giants like ORCL, ADBE, and CRM. Investor backlash against the anticipated hefty price tag reflects apprehensions about the economic feasibility of such an acquisition. Despite Ansys' significant economic moat, shaped by its extensive industry history and high switching costs, its recent revenue decline in Q3, attributed to China restrictions, adds a layer of complexity. Nonetheless, the potential long-term benefits of integrating Ansys into Synopsys, particularly amid rising semiconductor content, make it a strategically sound move. The short-term fluctuations in stock prices provide potential entry points for investors, even as uncertainties loom.

In a pharmaceutical landscape marked by sluggish M&A activity, the healthcare sector has witnessed a surge in deal-making as companies with ample cash reserves seek to strengthen their drug portfolios. This trend was underscored by Bristol-Myers Squibb (BMY) in its recent announcement of the acquisition of Karuna Therapeutics (KRTX), a clinical-stage biotech company specializing in neurological disease treatments, for a substantial $14.0 billion. BMY's strategic move follows a string of notable healthcare deals, including Roche Holdings' $2.7 billion acquisition of Carmot Therapeutics on December 4 and AbbVie's purchases of Cerevel Therapeutics for $8.7 billion and ImmunoGen for $10 billion in December and November, respectively. This acquisition marks BMY's second in recent times, following its purchase of oncology company Mirati Therapeutics (MRTX) on October 9, aimed at bolstering its cancer treatment portfolio. However, the KRTX acquisition holds particular promise for BMY's neuroscience business. At the heart of this deal lies KarXT, a potential groundbreaking treatment for schizophrenia and Alzheimer's disease psychosis, anticipating FDA approval by September 26, 2024. KRTX reported positive Phase 3 data for KarXT in March, demonstrating a significant 8.4-point reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo, a key milestone. The drug's tolerability and safety profile present a marked improvement over existing schizophrenia treatments, addressing serious side effects such as Parkinson's disease-like shaking, sedation, insomnia, and weight gain. By targeting different receptors (M1/M4 Muscarinic Receptors), KarXT aims to mitigate these adverse effects, as evidenced by clinical trial data. With an estimated 1.6 million people treated for schizophrenia in the U.S., KarXT, if approved, holds the potential to become a blockbuster, multi-billion-dollar drug for BMY. The offer price of $330 per share, a 53% premium from the previous day's closing price, reflects the company's confidence in the acquisition's strategic value. This move by BMY is noteworthy considering its existing growth challenges, particularly the decline in Revlimid sales by 41% to $1.4 billion and stagnant sales of Eliquis at $2.7 billion in Q3. Despite the expected dilution to EPS by approximately $0.30/share in 2024 due to financing costs, investors have responded positively, with BMY shares trading higher. This is a departure from the usual market trend, where acquiring companies often see a decline in their stock value on news of a buyout, especially if the deal is dilutive to earnings per share (EPS). Overall, the KRTX acquisition aligns with BMY's strategy to expand its neuroscience treatment portfolio and potentially offer a best-in-class solution for the challenging landscape of schizophrenia treatment.

Previous update:

In a landscape where overall merger and acquisition activity remains subdued, the pharmaceutical and biotech sectors are witnessing a surge in deal-making as cash-flush healthcare companies seek to enhance their drug portfolios. Bristol-Myers Squibb (BMY) exemplified this trend by announcing its $14.0 billion acquisition of Karuna Therapeutics (KRTX), a clinical-stage biotech firm specializing in neurological disease treatments. This move follows BMY's recent purchase of oncology company Mirati Therapeutics (MRTX) in October and aligns with a broader trend of robust deal-making in the healthcare sector, including high-profile acquisitions by Roche Holdings and AbbVie. The focal point of the acquisition is KarXT, a potential groundbreaking treatment for schizophrenia and Alzheimer's disease psychosis, anticipated to undergo FDA approval in September 2024. Karuna Therapeutics reported positive Phase 3 data for KarXT, demonstrating a significant reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo. Notably, the drug exhibits a promising tolerability and safety profile, addressing a common issue with existing schizophrenia treatments—severe side effects leading to medication discontinuation. The acquisition of Karuna Therapeutics positions BMY to potentially capitalize on KarXT as a blockbuster drug, catering to the estimated 1.6 million people treated for schizophrenia in the U.S. alone. With the potential for approval in additional indications like Alzheimer's disease psychosis, the total addressable market expands significantly. Despite the hefty $330 per share offer price, representing a 53% premium, investors have responded positively, driving BMY shares higher. The strategic move comes at a time when BMY faces a growth slowdown, particularly with its chemotherapy treatment Revlimid encountering heightened competition from generics. In Q3, Revlimid sales experienced a 41% decline, prompting BMY to explore new avenues for growth. While the acquisition is expected to be dilutive to earnings per share (EPS) by approximately $0.30 in 2024, BMY's willingness to make this significant investment underscores its commitment to expanding its neuroscience treatment portfolio and addressing the challenges associated with treating schizophrenia.

NIKE (NKE) is experiencing a notable downturn as its second-quarter (2Q24) earnings report falls short of expectations, casting doubt on the sports and athletic footwear giant's market dominance. Anticipation for improved margins and a brighter growth outlook was met with a mixed outcome. The company achieved gross margin expansion of 170 basis points year-on-year and 40 basis points sequentially, reaching 44.6%, attributed to inventory reduction efforts supporting stronger pricing. Despite navigating a highly promotional retail environment, NKE projects further gross margin expansion in Q3 (160-180 basis points) and Q4 (225-250 basis points). In tandem with cost containment measures, specifically a mere 1% increase in SG&A costs to $4.1 billion, NKE surpassed earnings expectations, with earnings per share (EPS) growing 21% year-on-year to $1.03. However, this positive news is overshadowed by sluggish sales in Q2 and a less optimistic sales outlook. North America witnessed a 4% revenue decline, with wholesale revenues down 2%, contrasting with the optimistic sentiment following strong reports from Dick's Sporting Goods and Foot Locker. Greater China's growth decelerated to 8%, raising concerns about NKE losing ground to competitors like lululemon. Despite solid demand during peak shopping periods, NKE faced relative weakness in business outside these peak days, particularly in its digital platforms, where lower-than-expected traffic was observed amid heightened promotional activities by competitors. The outlook for the next few quarters remains dim, leading to a downward revision of NKE's FY24 revenue growth forecast to approximately 1%, down from the previous mid-single-digit estimate. This performance prompts concerns that NKE might be ceding ground to competitors and losing its competitive edge. CEO John Donahoe recognizes the need to accelerate innovation and announces a multi-year product innovation cycle, introducing new franchises and platforms in the coming years. To finance these initiatives, NKE is implementing a $2 billion cost-savings plan centered on automation, technology use, streamlining efforts, and simplifying the product assortment. The key takeaway is that NKE's disappointing Q2 sales and 2H24 outlook raise concerns beyond macroeconomic factors, suggesting a potential loss of edge in product innovation, contributing to the current substantial selloff.

AAR Corp. (AIR) experiences a slight downturn following its Q2 (Nov) earnings report, signaling a dip in altitude despite positive prospects for calendar year 2024. This aviation services provider, catering to both commercial and defense aircraft, encountered a modest earnings beat, with a smaller upside compared to recent quarters. The focal point of concern lies in the top-line results, as revenue increased by 16.1% year-on-year to $545.4 million but fell short of analyst expectations. Sales to commercial customers, constituting 71% of total sales in Q2, rose impressively by 24% year-on-year, driven by robust demand for new and used parts. Conversely, government sales only increased by 1%. Within its business segments, the Parts Supply category saw a 24% increase in sales, fueled by strong demand for used serviceable material and expansion in commercial distribution activities. Repair & Engineering reported an 8% sales increase, attributed to strong performance in hangars and component repair operations, while Integrated Solutions experienced a 23% sales uptick due to increased flight hours. However, the Expeditionary Services segment faced challenges, with sales declining by 34% due to reduced mobility shipments of pallets to the Department of Defense, a consequence of diverted funding to the effort in Ukraine. Despite these challenges, there are positive indicators, such as the adjusted operating margin rising to 8.1%, driven by growth in commercial sales. Although AIR doesn't provide specific guidance, it notes a robust macro environment in the commercial aviation aftermarket, with customers expressing strong demand for services in calendar year 2024. Continued constraints on new aircraft deliveries and issues related to newer generation engines are anticipated to enhance demand for mid-to-late life aircraft, a core market for AIR. While the chart reflects an impressive trajectory for AIR, echoing Boeing's significant move since late October, the recent Fed announcement signaling a slowdown in rate hikes has been a key catalyst. The prevalence of bullish sentiment leading up to the Q2 report resulted in a slightly negative surprise with a modest EPS beat and a revenue miss. However, the outlook for calendar year 2024 appears promising.

Previous update:

Apogee Enterprises (APOG) reported a solid performance in Q3, achieving its ninth consecutive earnings beat with double-digit growth. Despite falling short on revenue expectations and revising down its FY24 revenue growth forecast, the company's focus on margin improvement showcased positive outcomes. Notably, APOG's cost-saving initiatives yielded impressive results, with gross margins expanding by 310 basis points to 26.6% and operating margins rising to 11.1%, surpassing the long-term target of 10%. This success prompted an upward revision of APOG's FY24 adjusted EPS guidance to $4.55-4.70 from $4.35-4.65. Architectural Glass played a significant role in driving Q3 performance, contributing to an 11.6% YoY increase in net sales to $91.0 million and supporting robust operating margins. However, Architectural Framing Systems and Architectural Services faced volume pressures, resulting in a 15.4% and 7.2% decline in net sales to $139.6 million and $94.7 million, respectively. This led to an overall 7.7% YoY drop in revenue to $339.7 million, missing estimates. The subdued volumes were attributed to ongoing uncertainties in the construction markets, where non-residential construction exhibited growth primarily driven by manufacturing projects, an area where APOG has limited participation. While APOG acknowledged the challenges posed by macroeconomic factors such as higher interest rates, tighter lending standards, and cost inflation, it remained optimistic about low single-digit growth rates in commercial construction for 2024. Despite the cautious outlook, APOG highlighted institutional and infrastructure projects benefiting from government funding, and the recent Federal Reserve signal of an interest rate pause could mitigate the impact on commercial construction, potentially leading to a shallower downturn. The company sees M&A opportunities emerging in a more favorable market, indicating a positive stance. While facing economic disruptions in 2024, APOG's strategic shift towards higher-margin segments positions it well to navigate challenges, especially if interest rates undergo a more significant decline.

Paychex (PAYX) faces a setback as slowing job growth impacts its outlook, resulting in a decline in its performance following Q2 results. Despite last quarter's optimism regarding potential FY24 revenue growth, PAYX now anticipates growth to fall within the initially forecasted 6-7% range. While Q2 showed resilience, with PAYX surpassing EPS and revenue estimates due to sustained demand from small and medium-sized businesses (SMBs), the subsequent quarter presented challenges. CEO John Gibson highlighted a moderation in job growth and wage inflation among small businesses, and observed softening in large client business segments, including HR outsourcing. Despite these challenges, PAYX experienced relative strength in various sectors, such as Professional Employer Organization (PEO), mid-market, human capital management (HCM), and retirement. 1H24 revenue growth in these areas reached 6%, propelled by new client acquisitions across PAYX's suite of HCM offerings and an uptick in PEO worksite employees. Although the macroeconomic backdrop poses challenges to job growth, companies are reassessing HR and benefits strategies due to the tight labor market and escalating healthcare costs. While PAYX's 6% top-line growth may seem moderate, the company's steady business performance remains an appealing quality. Revenue retention surpasses pre-pandemic levels, with record-high retention in the HR outsourcing solutions business. Despite external macroeconomic factors influencing a minor regression from the previous quarter, PAYX continues to exhibit earnings growth, with a 9% year-over-year increase in EPS. The Q3 operating margin guidance of 44-45% reflects expansion from the 40.2% achieved in Q2. However, significant upward movement in the stock is contingent on notable improvements in the labor market conditions, posing a challenge in the current scenario.

Carnival (CCL) is experiencing a surge in its stock value today after releasing its Q4 (Nov) earnings report, showcasing robust earnings and optimistic commentary on bookings. The cruise line reported a substantial 40.6% year-over-year increase in revenue, reaching a Q4 record of $5.40 billion, surpassing expectations. Despite this positive performance, CCL provided guidance for Q1 with an adjusted loss of approximately $(0.22), falling short of analyst predictions. The company also offered FY24 adjusted EPS guidance that was below analyst expectations. In evaluating the financials, adjusted EBITDA, a relevant metric for capital-intensive cruise ships, exceeded expectations at $946 million in Q4, surpassing prior guidance of $800-900 million and significantly outperforming the $(96) million loss from the previous year. Q1 adjusted EBITDA guidance stands at approximately $800 million, and for FY24, it is projected to be around $5.6 billion. Carnival highlighted its strong finish to FY23, achieving another record-breaking quarter and consistent outperformance throughout the year due to heightened demand across all brands. Q4 net yields exceeded those of a robust 2019, surpassing CCL's expectations. Regarding bookings, CCL entered FY24 with an unprecedented booked position, with nearly two-thirds of its occupancy already reserved for 2024 at substantially higher prices in constant currency. Notably, booking volumes during Q4 remained significantly elevated, surpassing both the prior year and 2019 comparable periods. Black Friday and Cyber Monday also saw record-breaking booking volumes, while European brands exhibited remarkable strength with double-digit booking volumes at considerably higher prices. In summary, Carnival's Q4 performance was solid, marked by positive results and strong demand, pricing, and bookings. Particularly noteworthy is CCL's assertion that its booked position for 2024 is the strongest ever recorded. Despite providing guidance below expectations, investors seem less affected, possibly anticipating conservative guidance from CCL, which is a characteristic of the company.

Cintas (CTAS) is experiencing a significant uptick in its stock value following the release of robust Q2 (Nov) results this morning. After a narrower beat in Q1, Cintas has returned to its customary double-digit EPS beat in Q2, coupled with favorable revenue performance. Notably, the highlight of the quarter was Cintas once again raising its FY24 EPS and revenue outlook by a margin surpassing the Q2 upside, signaling optimism for Q3-Q4. This pattern of upward adjustments in both Q1 and Q2 suggests management's confidence in the company's outlook for the second half of the fiscal year. Cintas serves as a valuable indicator of businesses' near-term prospects, renowned as the largest provider of work uniforms in the U.S. Additionally, it derives over half of its revenue from facility services encompassing cleaning supplies, mops, first aid cabinets, PPE, fire extinguishers, and alarms. The Uniform Rental and Facility Services segment, the larger of the two, witnessed an 8.2% year-over-year increase in revenue to $1.85 billion. Other revenue, with a substantial contribution from its First Aid segment, rose by 13.3% year-over-year to $526.6 million. Margins emerged as a positive aspect in Q2, with gross margin improving to 48.0% from the previous year's 47.0%, driven by robust volume growth and sustained operational efficiencies. Despite facing lower energy expenses, specifically in gasoline, natural gas, and electricity, by 40 basis points year-over-year, Cintas, heavily reliant on truck deliveries for uniforms, demonstrated resilience to external factors like fluctuating gas prices. Moreover, operational efficiency improvements were evident as the operating margin increased to 21.0% from 20.5% year-over-year, despite increased investments in selling resources, technology, and the management trainee program. Regarding EPS guidance, Cintas substantially increased its FY24 outlook to $14.35-14.65 from the previous $14.00-14.45, a move that could have been more conservative considering the remaining half of the fiscal year. The decision to raise FY24 projections by an amount exceeding the Q2 beat implies optimism for the second half, contributing to the stock's notable surge. In summary, Cintas impressively rebounded to report double-digit EPS beats after a narrow beat in Q1. The company's success can be attributed to robust volumes, leading to improved margins and operational efficiencies. Overall, Cintas remains a favorable choice with a consistent and predictable business model featuring a robust recurring revenue component. Additionally, the company benefits from the broader trend of businesses outsourcing functions to focus on their core operations.

Micron (MU) is experiencing a notable turnaround, with the challenging inventory situation in the data center, PC, and smartphone markets showing signs of improvement. The company, along with other chip makers, has faced difficulties due to elevated inventory levels, but the latest earnings report for Q1 indicates a positive shift. Improved demand is contributing to higher DRAM/NAND prices, leading to an upside in earnings. Micron's optimistic outlook extends to Q2, with the company guiding EPS, revenue, and gross margin above expectations, while expressing confidence in its prospects for FY24 and FY25. The recovery in the PC market, emphasized by semiconductor companies like Intel (INTC) and Advanced Micro Devices (AMD), is a key factor benefiting Micron. The healthier PC market, with demand from OEMs aligning closely with end-market demand, has positively impacted Micron's performance. Looking ahead, Micron foresees continued momentum, anticipating low-to-mid single-digit growth in PC unit volume for 2024 after experiencing double-digit declines in the past two years. A significant aspect of Micron's success lies in the data center end market, where GPU-enabled AI servers are gaining traction. These advanced servers, featuring higher bandwidth memory capacity and enhanced performance requirements, are addressed by Micron's new HBM3E chipset. Samples of HBM3E, shipped in Q1, are in the final qualification stages for use in NVIDIA's (NVDA) Grace Hopper GH200 and H200 platforms. In 2024, Micron expects to generate "several hundred million" dollars in HBM3E revenue as volume production ramps up, with growth accelerating into 2025. As the supply-demand imbalance levels out and generative AI becomes more integrated into PCs and smartphones with on-device capabilities, Micron anticipates continued improvement in pricing dynamics for DRAM and NAND in FY24. In Q1, the non-GAAP gross margin turned positive at 0.8%, surpassing previous guidance and demonstrating a significant improvement from the previous quarter. Q2 is expected to witness further expansion, with Micron guiding for a non-GAAP gross margin of 13.0%, +/- 1.5%. Micron's impressive Q1 earnings report, marked by a beat-and-raise scenario, indicates a transition from a downturn to a recovery in the memory space, with prospects of growth in FY24. Looking ahead to FY25, Micron envisions a record total addressable market as AI applications proliferate across the data center, PC, and smartphone markets.

Previous update:

Steelcase (SCS) experienced a significant rebound, surging by 12% from its lows, following a bearish response to its Q3 (Nov) earnings report that initially led to a 12% decline. The dip was triggered by a sales miss in the quarter, with revenues falling 5.9% year-over-year to $777.9 million. However, upon closer examination, investors reacted positively, attributing the revenue shortfall to order fulfillment patterns in the Americas division, impacted by isolated supplier issues. Steelcase is actively addressing these challenges and anticipates their resolution in Q4 (Feb). Amidst the transient revenue headwind in Q3, Steelcase is benefiting from various positive developments. Notably, the company has made strides in improving gross margins, a focal point of its structural shift since the pandemic altered traditional office work models. In Q3, gross margins expanded by 360 basis points year-over-year, a noteworthy acceleration compared to the 210 basis point improvement in the previous quarter. Despite falling short of revenue expectations, Steelcase exceeded earnings estimates, achieving a 50% growth in the bottom line to $0.30 per share. Orders stood out as another highlight, witnessing a 15% year-over-year growth and a 1% sequential increase, maintaining a relatively stable level observed throughout the year. The Americas segment experienced a 16% growth in orders, driven by robust demand in Steelcase's large corporate customer segment. Additionally, International orders increased by 10%, reflecting positive momentum in the improvements made in Steelcase's EMEA and Asia-Pacific businesses, with the latter recording a substantial 40% spike in orders in Q3. Steelcase concludes its comeback year with robust Q4 (Feb) predictions. The company anticipates a year-over-year gross margin improvement of 170 basis points to 31.5%. Projected adjusted EPS is $0.19-0.23, a significant increase from $0.19 in the year-ago period, with revenue expected to range between $765 million and $790 million. Supply chain disruptions in Q3, which extended delivery times, impacted revenue estimates, but Steelcase remains optimistic about continued growth. While the initial response to Steelcase's Q3 report triggered profit-taking, a deeper analysis revealed positive aspects of the quarter. However, the company expressed caution, acknowledging that although it aims for mid-term organic sales growth of 5-7%, current demand conditions suggest a more modest level of growth. Consequently, the substantial market movement could face challenges if the return-to-office trend unfolds more slowly than expected, potentially impacting order growth. Interestingly, peer MillerKnoll is not mirroring Steelcase's significant gains ahead of its NovQ report.

Facing investor pressure, FedEx (FDX) witnessed an 11% decline in its stock following an earnings per share (EPS) miss and a downward revision of revenue guidance for fiscal year 2024 (FY24). In Q2 (Nov), the company reported a 2.8% year-over-year decrease in revenue to $22.16 billion, slightly below expectations. Of greater concern was FDX's decision to lower its FY24 revenue outlook, anticipating a low single-digit decline compared to the previous forecast of nearly flat growth. Despite plans to repurchase an additional $1 billion of its shares in FY24, this move failed to alleviate investor concerns. Soft market conditions persisted in the U.S., with Q2 demand falling below FDX's expectations. The industry has now seen 10 consecutive quarters of decline in U.S. domestic average daily volume. International market pressures continued, even as FDX's Europe and EMEA teams managed to grow parcel volume. The Express segment, FDX's largest, faced challenges with a 6% year-over-year decline in revenue to $10.25 billion, attributed to market contraction and reduced fuel and demand surcharges. Global freight pounds saw an 18% year-over-year decline, influenced by lower Postal Service volume and weakness in industrial production. Despite these challenges, FDX highlighted the efficiency of its networks. The Ground segment experienced a 3% year-over-year revenue growth to $8.84 billion, driven by higher yield and volume. The Freight segment reported a 4% year-over-year decline in revenue to $2.36 billion, as lower shipments offset increased yield. However, the sequential decline in revenue moderated significantly as volume pressure eased, and revenue per shipment turned positive. Additionally, new customers joined following the Yellow bankruptcy/shutdown, with FDX retaining a majority of this volume. Looking ahead to the remainder of FY24, FDX expects revenue to be impacted by volatile macro conditions affecting customer demand. At FedEx Express, the company anticipates a continued shift in service mix negatively affecting revenue and operating income. The peak holiday season for this year is projected to be relatively similar to the previous year but in line with expectations. Overall, the Q2 report was disappointing for FedEx, marked by a substantial EPS miss and a reduction in FY24 revenue guidance. Previous quarters had seen slight revenue misses, but strong margins had offset these results. This time, however, the notable EPS miss and the downward revision of FY24 revenue guidance disappointed investors. Soft demand in the U.S., challenging macro conditions, and increased competition from the U.S. Post Office for smaller parcels have contributed to these setbacks. The stock's significant run-up since late October, reflecting elevated sentiment, compounded the impact. Sympathetically, UPS also experienced a decline. This report raises concerns about UPS's Q4 report in late January.

Winnebago's (WGO) fiscal first quarter reflected ongoing challenges in the RV and motorhome market, with revenue declining for the fifth consecutive quarter. Despite heightened promotional efforts, including increased discounts and allowances, to stimulate sales, the company faced margin and earnings pressures. The first-time shortfall in earnings per share (EPS) in over five years was attributed to a 130 basis points contraction in gross margin to 15.2% on a quarter-to-quarter basis and larger-than-expected expense upticks. While demand improved from the previous quarter, leading to better-than-expected first-quarter revenue, each of Winnebago's businesses still reported year-over-year sales declines, albeit at a reduced rate for two of the segments. Towable RVs experienced a revenue decline of less than 5%, a notable improvement from the 31% plunge in Q4, while motorhome sales were down by 28%, compared to a 43% drop in the previous quarter. Conversely, the Marine segment, a top performer in the last quarter, faced a 34% decline in sales this time. The Marine segment's challenging year-over-year comparison, with a 66% surge in the preceding period, underscored the difficult landscape. The growth in the Marine segment had been fueled by WGO's Barletta pontoon brand's market share gains and the broader growth in boating and water sports post-pandemic. Despite the anticipated challenging quarter, market participants were keen on whether Winnebago's outlook for fiscal year 2024 (FY24) would improve, given the significant easing of interest rates. While not providing formal EPS or revenue guidance, the company's executives, including CEO Michael Happe, expressed optimism that the RV destocking cycle is nearing conclusion. Happe reiterated the expectation that market conditions in both retail and wholesale could see improvement in mid-to-late 2024, aligning with the previously forecasted timeframe. While acknowledging the slow emergence of positive sales trends, there was disappointment that Winnebago did not adopt a more bullish tone regarding its FY24 outlook. The company appears to be managing expectations cautiously, considering the persistently challenging business conditions.

Despite General Mills' (GIS) Q2 earnings beat in November, the company faces a challenging stock performance as missed quarterly revenue projections and a downward revision of its FY24 organic net sales and adjusted EPS growth forecasts impact its outlook. While cost-saving efforts through the Holistic Margin Management (HMM) plan provided a boost, improving supply chains also benefited competitors, intensifying short-term competitive pressures. The positive impact on adjusted gross margins, up 180 basis points year-over-year, led to an eighth consecutive earnings beat. However, weak consumer demand, characterized by value-seeking behaviors, contributed to a 4-point year-over-year decline in volumes, accelerating from the previous quarter. The Pet segment, particularly premium pet food, experienced an 11-point volume decline, reflecting consumer shifts toward lower-priced alternatives. Despite challenges in North America Retail and Foodservice volumes, and International volume decline driven by China, GIS showcased resilience by maintaining buoyant segment margins. Although GIS adjusted its FY24 forecasts, anticipating negative 1% to flat organic net sales growth and a +4-5% increase in adjusted EPS, the company's ability to leverage cost-saving measures positions it well for future improvements in demand conditions. Despite near-term uncertainties, GIS may be approaching a bottom, having experienced a nearly -30% correction from its May all-time highs.

Previous update:

Affirm (AFRM) has undergone a remarkable reversal of fortune, marking a distinct shift from the challenging circumstances it faced at the outset of 2023 when its stock plummeted by 95% from its peak in November 2021. The past year has witnessed Affirm's stock orchestrating an impressive resurgence, driven by a more conducive business landscape and a series of positive developments. The latest boost emanates from the broadening of its collaboration with Walmart (WMT), enabling the provision of Affirm's deferred payment services at checkout kiosks in over 4,500 Walmart stores. This revelation has contributed significantly to a substantial upswing in AFRM's stock, which had already accrued over a 150% increase since the initiation of November. Taking a broader view underscores the impact of reduced interest rates, which has positively shaped sentiment. The decrease in interest rates not only fosters robust loan expansion but also mitigates risks of payment defaults and diminishes Affirm's expenses related to borrowing. The ongoing holiday shopping season has witnessed a heightened demand for deferred payment services, with a 42.5% year-over-year surge in shoppers availing such services on Cyber Monday, as reported by Adobe Analytics. As a dominant player in the deferred payment market, Affirm is evidently reaping significant benefits from this surge in holiday shopping. Various company-specific elements have contributed to Affirm's reversal of fortunes. In early November, the company disclosed Q1 results that surpassed expectations, showcasing accelerated growth in gross merchandise volume (GMV) by 28%. Significantly, categories like personal electronics, home & lifestyle, and sporting goods, which faced challenges in preceding quarters, displayed signs of improvement. Additionally, an extension of its collaboration with Amazon (AMZN) to encompass small businesses further elevated Affirm's prospects. This strategic move allows millions of small business proprietors on Amazon access to Affirm's installment loans. Amazon Business, with its substantial annual sales surpassing $30 billion, represents a considerable triumph for Affirm. The extended partnership with Walmart, where Affirm's deferred payment products were already accessible online, fortifies its standing in a competitive arena. As deferred payment services gain favor for their transparent terms devoid of late fees or compounded interest, Affirm is strategically positioned to capitalize on the trend, particularly with collaborations secured with two of the most significant retailers in the country.

Alphabet, the parent company of Google (GOOG), faces an escalating legal challenge, making headlines for the second time in a week due to a $700 million settlement in an antitrust case concerning its Google Play platform. This follows Epic Games' recent triumph against GOOG in a lawsuit over anticompetitive practices related to fees charged to app developers on Google Play. Although Epic Games rejected the settlement, announced now but reached in September, deeming it insufficient, a jury, unlike the previous case against Apple (AAPL), delivered the verdict. GOOG plans to appeal, but if unsuccessful, the repercussions for the company could surpass the disclosed settlement. Despite potential legal ramifications, investors appear relatively unfazed. The primary reason for their nonchalance is the limited contribution of Google Play to GOOG's overall revenue. In Q3, revenue from the Other Bets segment, encompassing Play, declined by 35% year-over-year to $288 million, constituting less than 4% of the total revenue. In contrast, Google advertising, comprising over 80% of Q3 total revenue at $54.7 billion, remains the dominant revenue source. A substantial threat to this advertising business could significantly impact GOOG's stock, with a looming danger stemming from the ongoing antitrust lawsuit filed three years ago. This lawsuit alleges that GOOG, holding around a 90% market share in search, wields an online advertising monopoly, constraining competition. The case, currently under the scrutiny of U.S. District Judge Amit Mehta, could lead to new restrictions on GOOG's collaborations with major tech firms. While legal challenges generate negative headlines, their impact on GOOG's financials or fundamentals remains limited for now. The outcome of the advertising business lawsuit may alter this perspective, but as of now, market participants are downplaying the legal setbacks and focusing on GOOG's expanding AI endeavors.

Accenture (ACN), the IT consulting firm, has opted to pause its bearish Q2 revenue forecast after reaching one-year highs last week. The company faced challenges in Q1 (Nov), with lower discretionary spending impacting consulting work and slower decision-making. Despite beating top and bottom-line expectations for the quarter, ACN projected Q2 revenues of $15.4-16.0 billion, representing a roughly 1% year-over-year decline at the midpoint—ACN's first quarterly sales drop since the pandemic. However, ACN reaffirmed its FY24 (Aug) projections, maintaining its EPS outlook of $11.97-12.23 and anticipating revenue growth of +2-5% in FY24. This positive outlook signals a belief that the worst challenges will swiftly resolve. ACN's upbeat figures and the optimistic FY24 outlook contribute to the overall positive sentiment, although the stock had shown signs of overextension leading into the Q1 report. Despite a recent climb of +17% from October lows and a six-day winning streak, yesterday's minor profit-taking ended the streak, and today's movement is relatively modest. The overarching enthusiasm for ACN likely stems from its focus on artificial intelligence (AI). While 2023 marked a year of AI experimentation, with deal sizes around $1.0 million, 2024 is expected to center around assisting clients in scaling their AI investments. The demand for AI continues to surge, with ACN reporting over $450 million in General AI sales in Q1, surpassing the total for FY23. Considering that less than 10% of companies utilize AI, according to ACN, significant potential lies ahead. Despite macroeconomic headwinds impacting ACN's Communications, Media & Technology (CMT) sector, resulting in a 10% sales decline in Q1, the company's other segments are experiencing growth. Health & Public Service saw a notable 13% increase, while Resources, Products, and Financial Services exhibited growth at 7%, 4%, and 2%, respectively. ACN's diversified portfolio prevented negative revenue growth in Q1, registering a 3% year-over-year improvement to $16.22 billion. Additionally, ACN remains on track with its planned business optimizations to reduce structural costs, contributing to a 20 basis points increase in adjusted operating margins year-over-year in Q1. This improvement drove a 6% rise in adjusted EPS to $3.27. Although macroeconomic conditions, especially in ACN's CMT segment and the U.K., continue to impact spending negatively, the company anticipates considerable demand for cloud migration, business modernization, and generative AI. ACN estimates that only 40% of enterprise workloads are in the cloud, with just 20% modernized, indicating significant opportunities ahead. Despite a light pullback today, even after an impressive rally to one-year highs, the market shares in the excitement.

HEICO (HEI +1.3%) concluded FY23 on a positive note, delivering a strong Q4 (Oct) report that exceeded expectations and garnered favorable reactions from investors. The aircraft components supplier outperformed in both EPS and revenue, with a noteworthy 53.6% year-over-year surge in revenue to $936.45 million, surpassing analyst projections. HEICO's recent completion of its largest-ever acquisition, Wencor, which closed on August 4, played a significant role in boosting Q4 results. The company achieved record quarterly sales and operating income, driven by outstanding sales performance in both operating segments. Notably, HEICO reported impressive 12% organic sales growth, primarily fueled by robust demand for its commercial aerospace products and services. Within its Flight Support Group (FSG) segment, responsible for selling jet engine and aircraft component replacement parts, sales soared by 74% year-over-year to a record $601.7 million in Q4. This growth was attributed to the Wencor acquisition and a substantial 20% organic growth. The FSG segment benefited notably from increased demand for its commercial aerospace parts and services, marking 13 consecutive quarters of sales growth amid sustained global commercial air travel expansion. In its Electronic Technologies Group (ETG) segment, specializing in electronic, data, microwave, and electro-optical products for military agencies and defense contractors, sales exhibited robust growth of 28% year-over-year, reaching a record $342.5 million. This growth was propelled by heightened demand, and the ETG segment notably achieved a 26% sequential growth in defense product sales during Q4. While HEICO refrains from providing specific guidance, it did offer insights into the FY24 outlook. The company anticipates sales growth in both segments, primarily driven by contributions from its FY23 acquisitions and sustained demand for a majority of its products. However, HEICO cautioned about potential challenges stemming from ongoing inflationary pressures, which may result in higher material and labor costs. The company also emphasized its commitment to the integration of Wencor. Overall, HEICO's performance in Q4 marked a substantial EPS upside, the largest since 3Q20, and the revenue upside exceeded typical expectations. The tailwind from the Wencor acquisition in Q4 may have been underestimated by some analysts. The positive results underscore the continued improvement in the commercial aerospace market, as evidenced by the notable surge in Boeing's (BA) share price since late October. It's noteworthy that HEI recently broke above its multi-month trading range in the $155-180 area, aligning with the upward trajectory seen in Boeing and other aerospace names since late October. Despite the strong reaction to the robust Q4 results, it appears that a positive outcome was already factored into the stock price. The favorable report is seen as a positive signal for other aerospace suppliers as the upcoming earnings season approaches.

Previous update:

Masonite International (DOOR) opened the door to the M&A market this morning, announcing its intention to acquire impact-resistant frame window and door maker PGT Inc. (PGTI) in a cash-and-stock deal valued at $3.0 bln. The transaction amounts to $41/share with PGTI shareholders receiving $33.50 in cash and $7.50 in common stock of DOOR, which represents a fairly modest premium of about 14% over last Friday's closing price. However, PGTI had already doubled in price on a year-to-date basis and reached all-time highs last Thursday, leaving less room for DOOR to offer an attractive price that it would be comfortable with. Still, DOOR is selling off sharply in the wake of this news even though it's only paying about 8x next year's earnings for PGTI. The main issue is that the company is partly financing the deal with new debt and/or equity, negatively affecting its EPS. Furthermore, investors may be questioning the timing of making a big splash in the M&A market when the company already has plenty on its plate and is trying to turn its own business around. In each of the past two quarters, DOOR's revenue has declined on a yr/yr basis, following flat revenue in 1Q23. During its Q3 earnings call in early November, DOOR noted that rising mortgage rates were continuing to put pressure on its end markets. The company saw "considerably softer demand" in both the new construction and the repair and remodeling markets, causing EPS and revenue to fall by 19% and 3.5%, respectively. Perhaps market participants would feel a little more comfortable if DOOR's business was starting to turn a corner and it could completely focus its attention on integrating the acquisition. Overall, though, we do believe that PGTI is a good fit for DOOR from a strategic and financial standpoint. PGTI's heavy-duty aluminum and vinyl frames are made to withstand hurricane-force winds and will nicely complement DOOR's more traditional interior and exterior residential doors. While PGTI has also been impacted by higher mortgage rates, its business has been a little more resilient. Last quarter, sales in the southeast segment grew by 5% to a record of $303 mln with strength in new construction (+6%) and repair and remodeling (+5%). A broader, more diversified product portfolio is a key positive to this deal, but DOOR also expects to realize approximately $100 mln in annual synergies over the next several years due to a combination of cost-saving and sales growth opportunities. In particular, the company should experience more cross-selling opportunities as it sells to a larger, more diverse customer base. Importantly, the transaction is expected to be accretive to DOOR's EPS in the first full year of ownership and accelerate thereafter, despite the use of new equity and/or debt to finance it. Although the idea of taking on more risk in an environment that's already very challenging isn't going over very well today, we do believe the acquisition could ultimately provide DOOR with a much-needed growth catalyst, especially if easing rates provide the business with a jumpstart.

Illumina (ILMN +1%) experiences an upswing in its recent positive trend following the disclosure of its intent to divest Grail, a healthcare company specializing in early cancer detection, acquired by Illumina over two years ago. This decision comes after an extended period of scrutiny by the European Commission (EC) regarding regulatory and legal aspects. Initially, Illumina maintained Grail as a separate entity during ongoing reviews, arguing that the EC lacked jurisdiction to scrutinize the merger due to Grail's absence of business operations in the European Union (EU). However, the EC, consistently investigating the proposed merger, expresses the desire for Illumina to divest Grail. Illumina recently submitted a Form 10 to the SEC, exploring options for Grail's divestiture, signaling an imminent separation from the acquisition. Illumina officially declares its intention to carry out a third-party sale or capital markets transaction for Grail, in compliance with the EC's directive, with terms expected to be finalized by the close of 2Q24. Following this decision, activist investor Carl Icahn, who nominated three directors to Illumina's Board and opposed the Grail purchase, communicates with shareholders. Icahn reiterates his dissatisfaction with Illumina's current directors, citing a breach of EU law during the Grail transaction's conclusion, incurring a cost of €432 million (currently under appeal). Overall, Illumina records $4.7 billion in impairment costs. With the resolution of the Grail divestiture, Illumina aims for a recovery from a challenging year, characterized by a 35% decline in shares, hitting a 10-year low last month. Despite Grail's impressive 110% year-over-year revenue growth to $21 million in Q3, it remained a challenge for Illumina's operations, posting a non-GAAP operating loss of $155 million. Illumina also revises its FY23 sales forecast for Grail to the lower end of the $90-110 million projection. Illumina faces broader challenges stemming from adverse macroeconomic and geopolitical conditions, including reduced demand in China and extended sales cycles due to customer purchasing constraints. While the company anticipates similarities between its 2024 outlook and the current challenges of 2023, optimism surrounds early indications of increased utilization for NovaSeq X, a new product with the potential to drive future demand. Pursuing cost-saving measures, Illumina surpasses its initial target by reducing annualized run-rate expenses by approximately $175 million. Despite major indices reaching one-year highs, Illumina strives for a recovery from decade lows. Ongoing uncertainties surround the Grail divestiture, including potential variations in proceeds between an outright sale and a spin-off. Nevertheless, the divestiture of Grail is expected to alleviate a significant burden for Illumina.

US Steel (X) secures a substantial premium as it enters into an acquisition agreement with Nippon Steel, Japan's largest steelmaker and a global industry giant. The agreed-upon deal values US Steel at $55 per share, exclusively in cash, translating to a total enterprise value of $14.9 billion. The Board of Directors of both companies has unanimously approved the transaction, with expectations for its completion in either Q2 or Q3 of 2024. US Steel had been in the midst of a strategic review over several months, with recent reports indicating consideration of bids surpassing $40. The surprising aspect for investors lies in the elevated $55 deal price, constituting a remarkable 40% premium over Friday's closing price of $39.31, and the all-cash nature further enhances its attractiveness. Notably, Cleveland-Cliffs (CLF) previously bid for X in the $35 range in August, albeit in cash-and-stock form, making US Steel's decision to hold out for a superior deal appear prudent. The rationale behind Nippon's move is its desire for international expansion. This acquisition complements its primary geographical focus on Japan, ASEAN, and India, contributing to an annual crude steel capacity of 86 million tons, inching closer to Nippon's target of 100 million tons annually. US Steel will maintain its name, and existing union contracts will be honored, providing Nippon with exposure to diverse end markets such as automotive, construction, consumer goods (packaging and appliances), electrical, industrial equipment, and oil country tubular goods (OCTG). On a potentially less favorable note, US Steel's facilities tend to be older, relying on relatively costlier union labor. Steel production methods include integrated producers (CLF, X), utilizing blast furnaces to create steel from raw materials, and mini-mills (CMC, NUE, STLD), which melt scrap in electric arc furnaces and are generally more efficient. However, X has expanded its exposure to mini-mill technology through its recent acquisition of Big River Steel. Overall, this deal is considered highly favorable for US Steel shareholders due to the substantial premium and all-cash structure, affirming management's decision to reject CLF's more modest offer in the previous summer. For Nippon, it signifies geographical diversification by establishing a stronger presence in the US market. While the premium appears considerable, the multiple offers received by X likely influenced the deal's closure at this level.

Previous update:

Investors are reevaluating their stance on Scholastic Corp (SCHL) after a challenging Q2 report. The renowned publisher and distributor of children's and young adult books, featuring titles like Harry Potter and Hunger Games, faced setbacks in its school-based channels during the crucial back-to-school second quarter. The repercussions included an earnings per share (EPS) shortfall and a downward revision of FY24 revenue guidance, with a new forecast indicating flat year-over-year revenue, compared to the previous guidance of 3-5% growth. Notably, school book club revenues saw a significant 44% year-over-year decline to $32.4 million, leading to a 6% decrease in revenue for the Children's Book Publishing and Distribution segment, totaling $392.8 million. While the decline in book club revenue was partially intentional as SCHL reduced unprofitable promotional offers, external factors played a more substantial role. During the earnings call, CEO Peter Warwick highlighted the growing complexity and challenges in the U.S. school environment, where polarization among schools and school boards has increased. Simultaneously, rising student absenteeism and teacher shortages are putting additional pressure on schools and educators, leading to more restrictions on how reading is taught. Compounding the issues, a slowdown in consumer spending has hampered sales in the School Reading Events division. SCHL anticipates that these challenges, influenced by industry dynamics and macroeconomic factors, will persist throughout the remaining school year, prompting a downward adjustment of its FY24 guidance. Despite these challenges, there are positive aspects to consider. SCHL has been actively repurchasing its stock, amounting to $58 million during Q2, and has authorized an additional $66 million for share repurchases. This move reflects confidence in SCHL's long-term prospects, driven by its strong position in the children's book market and the ongoing emphasis on literacy in education and families. Moreover, recent weeks have shown signs of a sales rebound in SCHL's school-based business, indicating a potential turnaround from the recent decline. While the enhanced share buyback program provides some reassurance, the consecutive challenging quarters position SCHL as a "show me stock," requiring tangible improvements in results to regain investor confidence.

Hershey Foods (HSY -1%) continues to face challenges, marked by a recent downgrade to "Neutral" from "Buy" by BofA Securities, adding to a series of downgrades over the past two months since the company surpassed Q3 earnings and sales expectations. This turbulent period for HSY began in the latter half of the year, with shares steadily declining after reaching all-time highs in May following an impressive Q1 report. Despite a more than 30% drop in the last six months, the stock may be finding a bottom as it consolidates. Persistent headwinds, such as the growing popularity of weight-loss drugs (GLP-1s) and ongoing cost inflation, remain, but there are positive indicators that could signal a more significant turnaround. Adjusted gross margins have consistently expanded throughout the year, aided by several price hikes. HSY is content with its current market position across various categories and, while open to potential further pricing actions to counter cost inflation, the company is relying on upcoming capacity additions to meet demand and maintain margins, particularly in its Sweet segment. Despite fluctuating volume growth during FY23, HSY has sustained volumes, never experiencing a decline greater than low single digits. The brand's portfolio, featuring well-known names like Reese's and Hershey Kiss, minimizes the risk of consumers trading down to generic brands. While private labels have seen a minor uptick, it remains a small part of HSY's business, making a significant impact unlikely. HSY currently remains unaffected by the rise in GLP-1s, anticipating no immediate material impact on its business. While the long-term effects of weight-loss treatments on overall growth are uncertain, HSY, like industry peers PepsiCo (PEP) and Conagra (CAG), is not overly concerned. In case of rapidly climbing adoption rates, HSY can leverage strategies such as enhancing its portfolio with smaller snack sizes and exploring opportunistic mergers and acquisitions. Despite a prolonged decline since May, HSY stands out in the consumer packaged goods sector with an estimated nearly 50% share of the U.S. chocolate market and a robust portfolio of unique products. While downward pressure may persist into 2023 due to tax loss harvesting, HSY appears close to a potential bottom, offering significant upside as the new year approaches.

Costco (COST) is witnessing a surge in investor interest after delivering a strong Q1 report, defying the trend of disappointing holiday shopping seasons for many retailers. The company reported better-than-expected 1Q24 earnings, highlighting an improvement in discretionary merchandise trends. While there was no announcement of a membership price hike, Costco declared a special cash dividend of $15 per share, further enhancing its quarterly performance. Similar to the previous quarter, Costco experienced robust in-store traffic, with a 4.7% increase in shopping frequency globally, contributing to a 3.8% rise in adjusted comparable sales. Food and sundries remained standout categories, with consumers favoring bulk purchases for value. Notably, there's a positive shift in demand for non-food categories, echoing the trend observed in the previous quarter, where big-ticket items like appliances, jewelry, electronics, and home furnishings showed significant improvement. In Q1, this momentum continued, particularly for appliances, registering year-over-year growth in the mid-20% range. The strength in categories like TVs, with high-single-digit growth, offset the softness seen in other consumer electronics like computers. The growing demand for non-food and big-ticket products is reflected in Costco's eCommerce same-store sales growth, which surged to +6.3%, compared to +1.1% in Q4, +0.3% in Q3, and -9.6% in Q2 of the previous three quarters. Big-ticket categories constitute a substantial portion, accounting for about 50-60% of Costco's total eCommerce sales. Membership renewal rates and total membership continue to rise for Costco. In the U.S. and Canada, the renewal rate increased by 10 basis points to 92.8%, while paid household members grew by 7.6% year-over-year to 72.0 million. During the earnings call, CFO Richard Galanti emphasized Costco's ability to retain and add members, leveraging the increased volumes during the pandemic years. While inflation cools off, there is speculation that Costco might implement a membership price hike soon, considering the last fee increase was in June 2017. Although no such announcement was made, Mr. Galanti hinted that a price hike is a matter of when, not if. The key takeaway from Costco's Q1 results and positive commentary on recent sales trends is its clear victory in the retail space this holiday season. Budget-conscious consumers are flocking to its stores, drawn by the pursuit of better values.

Darden Restaurants (DRI) is experiencing a modest decline despite reporting respectable Q2 (Nov) earnings today. DRI, operating various restaurant chains, including Olive Garden, LongHorn Steakhouse, and recently acquired Ruth's Chris Steak House, marked its first full quarter of Ruth's Chris results. Notably, DRI achieved its first double-digit EPS beat in nine quarters, though revenue aligned with expectations. The company raised its FY24 adjusted EPS guidance to $8.75-8.90 from $8.55-8.85 but slightly adjusted down FY24 revenue guidance to $11.5 billion from $11.5-11.6 billion. Q2 comps for DRI stood at +2.8% on a consolidated basis, a decline from Q1's +5.0% and Q4's +4.0%. Leading the comps were LongHorn at +4.9%, followed by Olive Garden at +4.1%, while Fine Dining comps lagged at -1.7%. DRI slightly reduced its FY24 comp guidance to +2.5-3.0% with two quarters remaining. While experiencing softness in Fine Dining brands during Q2, DRI is encouraged by strong holiday bookings. In-line sales coupled with strong upside EPS suggests better-than-expected margins. Margin growth was attributed to positive comps, robust labor management, and lower-than-anticipated restaurant and commodities expenses. Food and beverage expenses showed a 190 bps improvement YoY, driven by pricing leverage. Total commodities inflation was flat YoY and slightly better than internal expectations. Despite some consumer pressures, DRI's check softness is offset by lower inflation. The company adjusted down its FY24 sales guidance while raising its earnings outlook. Traffic remains flat to slightly negative for the full year. Although investors may be reacting to the comparatively smaller comp number than the prior two quarters, DRI contends that it was lapping tough +7.3% comps from last year. Additionally, the stock had seen a +24% increase from mid-Oct lows, possibly factoring in some positive news. This report may serve as a slight positive for other casual restaurant chains set to report in the upcoming earnings season, including BJRI, BLMN, CAKE, EAT, TXRH.

Homebuilder Lennar (LEN -1%) achieved strong results in Q4 (Nov), surpassing new orders and deliveries forecasts, and exceeding analysts' earnings and sales estimates, maintaining a trend seen throughout FY23. However, a notable difference this time was LEN missing its gross margin target in Q4 for the first time all year, posting 24.2% against its 24.4-24.6% prediction. Despite a mild pullback due to this development, LEN's shares had soared over +45% since November 1 and +10% in the past week to record highs. The slight decline today reflects investors taking some risk off the table. LEN's performance is supported by optimism around potential Federal Reserve interest rate cuts next year, with mortgage rates dropping below 7.00%, an approximately 80 bp decrease from late October. During most of Q4, mortgage rates climbed, and LEN maintained incentives for affordability, impacting gross margins more than anticipated. The average home price also contracted, with Q4's average sales price per home at $441K, down from $448K last quarter and $483K a year ago. Management expects the average sales price to slide further in FY24, estimating around $420K. Despite these challenges, headline numbers reflected healthy demand, with new orders growing 32% yr/yr to 17,366. In Q4, LEN's top line grew 7.8% yr/yr to $10.97 billion, supported by a 19% increase in deliveries to 17,366. Positive demand dynamics continue into FY24, with Q1 (Feb) projections expecting robust new orders (17,500-18,000) and deliveries (16,500-17,000), with gross margins relatively flat yr/yr at 21.00-21.25%. For the full year, LEN predicts deliveries to increase 9.5% yr/yr to 80,000. While LEN did not provide FY24 gross margin forecasts due to interest rate variability, the overall outlook remains positive, supported by sustained demand despite higher interest rates. As mortgage rates are expected to drop, homebuilders like LEN, along with peers such as D.R. Horton (DHI), KB Home (KBH), PulteGroup (PHM), and Toll Brothers (TOL), are poised to maintain their upward momentum, although a pullback following the substantial rise is likely overdue.

Previous update:

Investors are reevaluating their stance on Scholastic Corp (SCHL) after a challenging Q2 report. The renowned publisher and distributor of children's and young adult books, featuring titles like Harry Potter and Hunger Games, faced setbacks in its school-based channels during the crucial back-to-school second quarter. The repercussions included an earnings per share (EPS) shortfall and a downward revision of FY24 revenue guidance, with a new forecast indicating flat year-over-year revenue, compared to the previous guidance of 3-5% growth. Notably, school book club revenues saw a significant 44% year-over-year decline to $32.4 million, leading to a 6% decrease in revenue for the Children's Book Publishing and Distribution segment, totaling $392.8 million. While the decline in book club revenue was partially intentional as SCHL reduced unprofitable promotional offers, external factors played a more substantial role. During the earnings call, CEO Peter Warwick highlighted the growing complexity and challenges in the U.S. school environment, where polarization among schools and school boards has increased. Simultaneously, rising student absenteeism and teacher shortages are putting additional pressure on schools and educators, leading to more restrictions on how reading is taught. Compounding the issues, a slowdown in consumer spending has hampered sales in the School Reading Events division. SCHL anticipates that these challenges, influenced by industry dynamics and macroeconomic factors, will persist throughout the remaining school year, prompting a downward adjustment of its FY24 guidance. Despite these challenges, there are positive aspects to consider. SCHL has been actively repurchasing its stock, amounting to $58 million during Q2, and has authorized an additional $66 million for share repurchases. This move reflects confidence in SCHL's long-term prospects, driven by its strong position in the children's book market and the ongoing emphasis on literacy in education and families. Moreover, recent weeks have shown signs of a sales rebound in SCHL's school-based business, indicating a potential turnaround from the recent decline. While the enhanced share buyback program provides some reassurance, the consecutive challenging quarters position SCHL as a "show me stock," requiring tangible improvements in results to regain investor confidence.

Previous update:

Moderna's (MRNA) outlook beyond the COVID-19 era receives a boost with positive developments for its melanoma drug, mRNA-4157. As the demand for its COVID-19 vaccine wanes from the peak witnessed during the pandemic, causing a decline in shares over the past two years, uncertainty looms over Moderna's future prospects. Today, the company, in collaboration with Merck, unveiled promising data from the Phase 2b study of mRNA-4157, an investigational treatment for melanoma patients post-surgery. The study revealed a 49% reduction in the risk of recurrence or death when mRNA-4157 is combined with Merck's KEYTRUDA, compared to KEYTRUDA alone. These positive efficacy results mark a significant milestone for Moderna's mRNA-based technology, the foundation of its COVID-19 vaccine and other respiratory vaccines in development, notably for RSV. mRNA-4157 stands out as a personalized treatment, utilizing the patient's tumor genetic profile to guide T-cells in attacking cancerous cells. Moderna's CEO, Stephane Bancel, anticipates a fully enrolled Phase 3 trial by the second half of 2024, with a potential accelerated launch in 2025, pending continued positive study outcomes. While 2024 is expected to be challenging for Moderna with declining COVID-19 vaccine sales, the potential launch of the RSV vaccine in late 2023 and a conditional launch of mRNA-4157 in 2025 could signify a turning point for the company. The encouraging data for mRNA-4157 represents a crucial step in Moderna's strategic mission to introduce fifteen new treatments over the next five years.

Jabil (JBL) experiences a rebound in its stock value after an initial dip following its Q1 (Nov) results. Despite a modest Q1 report, with earnings and sales beating expectations and a reiterated FY24 (Aug) outlook, Jabil's shares faced selling pressure initially. However, the stock quickly regained strength, currently trading above its flatline. Jabil's Q1 results were not particularly stellar, but the company's management remains optimistic about economic conditions, refuting concerns raised last month when the company reduced its FY24 guidance due to softening demand from short-term inventory corrections. Jabil maintains that these inventory adjustments are temporary. As a major player with a notable customer base, including tech giants like Apple (AAPL), NVIDIA (NVDA), and Amazon (AMZN), Jabil's reduced outlook signaled a broader slowdown in end-customer demand across the tech industry, echoing warnings from its electronics manufacturing services (EMS) peers. While Jabil faced selling pressure after lowering financial targets last month, its shares have held above levels seen before its upbeat Q4 (Aug) report in late September. The current upward trajectory in stock price reflects overall investor optimism as Jabil enters 2024 with customer inventory adjustments progressing as anticipated. The impact of inventory corrections is evident in Jabil's Q1 results, with revenue declining by 13% YoY to $8.39 billion, marking its most significant quarterly drop in years. The Diversified Manufacturing Services (DMS) segment fared better than Electronics Manufacturing Services (EMS), experiencing a 6% decline to $4.8 billion compared to a 21% drop to $3.6 billion. Weaknesses were observed in connected devices, 5G, networking, and digital print, while automotive and healthcare end markets demonstrated relative strength. Despite the challenges, operating margins provided a positive note, expanding by 50 basis points YoY to 5.3%, contributing to a 13% increase in adjusted EPS YoY to $2.60. DMS played a pivotal role in this growth, with operating margins expanding by 180 basis points YoY, while EMS saw a more modest 30 basis points margin expansion. Looking ahead, Jabil maintains its expectations for FY24, anticipating adjusted EPS of $9.00 and revenues of $31.0 billion. The company remains committed to delivering adjusted free cash flow above $1.0 billion this year. While end-market demand has experienced fluctuations in recent months, Jabil's Q1 results and reaffirmed FY24 targets indicate that the situation is progressing according to internal expectations. The company foresees enduring inventory corrections in the next couple of quarters, with a potentially less challenging market in the latter half of FY24.

Adobe (ADBE) is facing a decline in its stock value today despite reporting robust Q4 (Nov) results last night. The digital document giant has maintained an impressive trend, achieving five consecutive double-digit EPS beats following four small beats. Adobe also marked a significant milestone with its first-ever $5 billion quarter. However, the guidance for Q1 (Feb) and FY24 is impacting shares negatively. Although Adobe provided an upside EPS guidance for Q1, the mid-point of FY24 EPS guidance fell below expectations. In terms of business segments, the Digital Media segment performed well, with revenue growing 13% YoY to $3.72 billion, surpassing prior guidance. Adobe's other major segment, Digital Experience, saw a 10% YoY revenue increase to $1.27 billion, aligning with its prior guidance. Adobe highlights global demand for content as a positive factor, with Creative Cloud remaining the preferred platform for creators across various domains. Q4 marked a record quarter for Creative Cloud, generating $3 billion in revenue, driven by the success of the Firefly family of creative generative AI models. On the Document Cloud side, Adobe emphasizes its leadership in digital documents, citing growth in Acrobat Web users and strong demand for Acrobat on mobile. The pending Figma acquisition, under scrutiny for anti-competitive concerns by the US DOJ and the EU, presents challenges with preliminary objections and provisional findings of competition concerns. Despite this, Adobe remains optimistic about the strategic opportunity with Figma. While Q4 reflects another strong quarter for Adobe, the less optimistic guidance for FY24 is impacting the stock today, particularly the revenue guidance for Q1. Adobe's typically in-line revenue guidance for the next quarter has led to concerns among investors. Additionally, updates on the Figma deal and potential regulatory hurdles are contributing to the decline in share value. Some investors may be leveraging this report to secure profits, considering the recent substantial increase in the share price, which has risen by 80% since mid-May.

Previous update:

Southwest Air (LUV) is experiencing a decline in its stock value despite a largely positive 4Q23 update, reflecting a robust increase in travel demand during the Thanksgiving holiday period. Despite anticipating unit revenue (RASM) to fall between -9% and -10%, a narrower range than the prior guidance of -9% to -11%, LUV is not rallying as expected. This can be attributed to two primary reasons. Firstly, the strong demand during the Thanksgiving period is well-known in the industry, as evidenced by Delta Air Lines (DAL) reaffirming its Q4 EPS guidance with record revenue during this time. The market had already priced in this surge, leading to a sell-the-news reaction as investors secure recent gains. Secondly, unlike JetBlue Airways (JBLU), LUV did not raise its Q4 EPS guidance. Surprisingly, LUV increased its fuel cost estimate, presenting a modest headwind to its expected Q4 earnings. While LUV maintained its 2024 capacity growth expectations at 10-12%, it adjusted annual targets beyond 2024 to low-to-mid single-digit growth, potentially alleviating concerns about rising industry capacity impacting airfare prices. While LUV benefited from the holiday-related travel surge, the market's focus on the unaltered earnings guidance, in contrast to JBLU, has led to the subdued market response.

ABM Industries (ABM) is surging to one-year highs with a notable 13% gain, driven by Q4 (Oct) results that surpassed market concerns. The facility services provider faced challenges due to a sluggish commercial property market influenced by the prevalent hybrid work model. Following the company's first earnings miss in over two years last quarter and a downward revision of its FY23 EPS guidance, ABM implemented cost structure adjustments in Q3 (Jul). However, Q4's better-than-expected performance, coupled with a FY24 EPS projection of $3.20-$3.40, in line with analyst forecasts, is swiftly easing previous apprehensions. ABM also announced an additional $150 million for share buybacks. Q4 revenues grew by 4.4% year-over-year to $2.1 billion, lifting the bottom line by 13.5% to $1.01. While the Business & Industry segment faced challenges with slow growth due to static office density rates and commercial office vacancies, other segments experienced robust expansion. Manufacturing & Distribution, Education, Technical Solutions, and Aviation posted solid growth, with the latter soaring by nearly 16% to $248.2 million, reflecting strength in leisure and business travel markets. ABM anticipates growth in all segments except Business & Industry, which may remain subdued due to 2024 office lease expirations. Despite challenges from remote work, ABM is poised for solid growth in 2024, particularly with notable performance in segments outside Business & Industry.

Tesla (TSLA) is facing a significant recall of over 2 million vehicles, prompted by concerns about the effectiveness of its Autopilot system in preventing driver misuse, as highlighted by the National Highway Traffic Safety Administration (NHTSA). This recall follows a two-year investigation by the NHTSA into over 950 crashes potentially involving Tesla's Autopilot system. Despite the alarming nature of the recall, it differs from traditional recalls as Tesla plans to address the safety concerns through a free software update for Autopilot, minimizing costs. While recalls typically have a short-lived impact on automakers' stock prices, another crucial financial development for Tesla is the potential loss of a $7,500 federal tax credit for its lowest-priced Model 3 and long-range vehicles after December 31, 2023. This news could influence consumer behavior, prompting some to make vehicle purchases before year-end to secure the tax credit, particularly as the Model 3 represents a significant portion of Tesla's deliveries. It's noted that Tesla has been warning consumers about the impending reduction in the tax credit, with the possibility of the entire credit being eliminated. This financial consideration may drive sales in the final weeks of 2023, potentially aiding Tesla in achieving its ambitious Q4 delivery target of around 480,000 vehicles and its goal of delivering 1.8 million vehicles in 2023. Despite the attention garnered by the recall news, the potential loss of the tax credit is deemed more impactful from a financial standpoint and could have a meaningful effect on Tesla's sales strategy for the remainder of the year.

Pfizer (PFE) is grappling with a decline in its stock price, approaching pandemic lows, following the release of downbeat guidance for FY24, projecting earnings and revenue below consensus estimates. The company anticipates FY24 EPS in the range of $2.05 to $2.25, representing a 39% year-over-year increase at the midpoint but falling significantly short of consensus expectations. Additionally, revenue is forecasted to be between $58.5 billion and $61.5 billion, reflecting roughly flat growth year-over-year. The subdued outlook is attributed to diminishing demand for its COVID-19 vaccine Comirnaty and treatment Paxlovid, with a combined revenue estimate of approximately $8.0 billion, notably below street estimates. While the downbeat earnings forecast was expected due to the impact of the $43 billion Seagen (SGEN) acquisition in March, PFE's lighter-than-expected revenue projection surprised the market, driven by the waning demand for COVID-19-related products. PFE has faced several challenges, including declining sales of Comirnaty and setbacks in its weight-loss drug danuglipron. Despite these setbacks and the looming patent expirations for key drugs, PFE remains optimistic about its robust pipeline, boosted by recent acquisitions like Biohaven Pharma and Seagen. The company aims for at least $4.0 billion in net cost savings by the end of 2024 through restructuring efforts, which should alleviate the impact on earnings related to COVID-19 vaccines. PFE's strategic initiatives, coupled with its strong financials and an attractive valuation, could position the company for recovery after a challenging year. While the stock price has experienced a significant decline, PFE's underlying fundamentals and the potential of its acquisitions may signal an opportunity for future growth despite current headwinds.